Am J Clin Pathol

1. FERREIRA EO, Schefter AM, Brustad A, Klein ME, et al
   Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice.
   Am J Clin Pathol. 2024;162:75-85.
   

   >> Share

   
   

   
   Clin Cancer Res

2. NIEF CA, Hammer PM, Wang A, Charu V, et al
   Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
   Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158.
   

   >> Share

   
   
3. YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al
   Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
   Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836.
   

   >> Share

   
   

   
   Gynecol Oncol

4. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
   Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
   Gynecol Oncol. 2024;188:97-102.
   

   >> Share

   
   
5. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
   NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
   Gynecol Oncol. 2024;188:103-110.
   

   >> Share

   
   
6. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
   Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
   Gynecol Oncol. 2024;188:52-57.
   

   >> Share

   
   
7. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
   Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
   Gynecol Oncol. 2024;186:199-203.
   

   >> Share

   
   
8. NELSON AT, Harris AK, Watson D, Kamihara J, et al
   Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
   Gynecol Oncol. 2024;186:117-125.
   

   >> Share

   
   
9. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
   The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
   Gynecol Oncol. 2024;186:110-116.
   

   >> Share

   
   
10. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    

    >> Share

    
    
11. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    

    >> Share

    
    
12. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    

    >> Share

    
    
13. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    

    >> Share

    
    

    
    Int J Gynecol Pathol

14. WALIA A, Ladwig NR, Mak JS, Rabban JT, et al
    Prevalence of Occult Ovarian Cancer and Metastatic Breast Cancer in Ovarian Ablation Specimens of Patients With Hormone Receptor-Positive Breast Cancer: Implications for Tissue Sampling Strategies, Early Ovarian Cancer Detection and Resource Utilizati
    Int J Gynecol Pathol. 2024 Jun 26. doi: 10.1097/PGP.0000000000001055.
    

    >> Share

    
    

    
    J Natl Cancer Inst

15. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    

    >> Share

    
    

    
    Oncol Rep

16. DONG YF, Zhang J, Zhou JH, Xiao YL, et al
    Mitochondrial?associated endoplasmic reticulum membrane interference in ovarian cancer (Review).
    Oncol Rep. 2024;52:112.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share